Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6016 participants.

Also called NCT04435626

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,016 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04435626
  • EudraCT 2020-000306-29
Main results
  • Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure Journal of cardiac failure, 2024-09 DOI, PubMed 38740173
Other papers using this trial's data
  • A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF European heart journal. Cardiovascular pharmacotherapy, 2026-05-19 DOI, PubMed 41697954, PMC13185745 In the PMC Open Access subset under CC BY.
  • Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial European journal of heart failure, 2025-11 DOI, PubMed 40377177, PMC12765042 In the PMC Open Access subset under CC BY-NC.
  • Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial JAMA cardiology, 2026-06-01 DOI, PubMed 41903171, PMC13033172 In the PMC Open Access subset under CC BY-NC-ND.
  • EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF JAMA cardiology, 2026-05-01 DOI, PubMed 41903165, PMC13033173 In the PMC Open Access subset under CC BY-NC-ND.
  • Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure Circulation, 2025-01-14 DOI, PubMed 39340828, PMC11732259 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial Circulation, 2025-01-07 DOI, PubMed 39342512, PMC11670913 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF JACC. Heart failure, 2026-06 DOI, PubMed 41642173
  • Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial European journal of heart failure, 2026-05-02 DOI, PubMed 41771075
  • Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial JAMA cardiology, 2025-02-01 DOI, PubMed 39332395, PMC11581494 In the PMC Open Access subset under CC BY-NC-ND.
  • Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial JAMA cardiology, 2025-08-01 DOI, PubMed 40531488, PMC12177723 In the PMC Open Access subset under CC BY-NC-ND.
  • Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial JACC. Heart failure, 2026-01 DOI, PubMed 40208137
  • Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS-HF trial European journal of heart failure, 2025-12 DOI, PubMed 40916719
  • Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial JAMA cardiology, 2025-07-01 DOI, PubMed 40156827, PMC11955084 In the PMC Open Access subset under CC BY-NC-ND.
  • Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial Journal of the American College of Cardiology, 2025-01-21 DOI, PubMed 39490700
  • Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial JACC. Heart failure, 2026-01 DOI, PubMed 40232214
  • Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial The lancet. Diabetes & endocrinology, 2025-02 DOI, PubMed 39818225
  • Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF JAMA cardiology, 2025-06-01 DOI, PubMed 40042880, PMC11883611 PubMed links an erratum for this paper. Erratum: PMID 40238143 Not in the PMC Open Access subset.
  • Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial JAMA cardiology, 2025-07-01 DOI, PubMed 40397470, PMC12096322 In the PMC Open Access subset under CC BY-NC-ND.
  • Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial JAMA cardiology, 2025-01-01 DOI, PubMed 39550721, PMC11571069 In the PMC Open Access subset under CC BY-NC-ND.
  • Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF Circulation. Heart failure, 2026-02 DOI, PubMed 41608790
  • Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF Journal of the American College of Cardiology, 2025-01-21 DOI, PubMed 39665701
  • Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA cardiology, 2025-01-01 DOI, PubMed 39550716, PMC11571067 In the PMC Open Access subset under CC BY-NC-ND.
  • Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial European journal of heart failure, 2025-08 DOI, PubMed 40222820, PMC12482838 In the PMC Open Access subset under CC BY-NC.
  • Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction JACC. Heart failure, 2026-04 DOI, PubMed 41364043
  • HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial JACC. Heart failure, 2026-11 DOI, PubMed 42663335
  • Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial JAMA cardiology, 2025-07-01 DOI, PubMed 40159247, PMC11955905 In the PMC Open Access subset under CC BY-NC-ND.
  • Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction JACC. Heart failure, 2025-10 DOI, PubMed 40857999
  • The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF European journal of heart failure, 2025-08 DOI, PubMed 40300840, PMC12482849 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Finland, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Slovakia, South Korea, Spain, Taiwan, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04435626. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-14 (actual); primary completion 2024-05-15 (actual). Results posted on 2025-08-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
Acronym
FINEARTS-HF
Condition
Heart Failure
Intervention (Drug)
Finerenone (BAY94-8862)
Intervention (Other)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04435626
Content hash
ab746279c89276968fdf44c574cf6b3ce2181245a218cefe13a4f286abc8ed19